Archive · 2 Sep 2025
AstraZeneca's Baxdrostat Lowers Blood Pressure in Trials
Imagine a new medicine called Baxdrostat, made by AstraZeneca, that helps lower very high blood pressure.
This medicine blocks a hormone called aldosterone, which causes blood pressure to rise.
In a study with many people, it successfully reduced blood pressure.
The improvement lasted for at least 32 weeks.
This could help millions of people around the world, significantly reducing the risk of heart attacks, strokes, and other serious health issues.
AstraZeneca developed a new drug called Baxdrostat to treat high blood pressure.
The drug reduced blood pressure by up to 10 points in clinical trials.
Blood pressure improvements were sustained for at least 32 weeks.
The drug works by blocking the hormone aldosterone.
4 in 10 patients taking the drug achieved normal blood pressure levels.
- Who
- Patients with uncontrolled hypertension
- What
- Baxdrostat, a new drug, significantly lowered blood pressure in trials.
- When
- Results observed for at least 32 weeks.
- Where
- Across 214 clinics worldwide.
- Why
- To provide a new treatment option for hypertension.
- Drug Name
- Baxdrostat
- Developed By
- AstraZeneca
- Trial Phase
- Phase III
- Blood Pressure Reduction
- Up to 10 mmHg (systolic)
- Study Duration
- At least 32 weeks
- Patients Achieving Normal Blood Pressure
- 4 in 10
